Larimar Therapeutics Reports Positive Friedreich's Ataxia Treatment Data, Adjusts Dosing Regimen for Anaphylactic Risks

Larimar Therapeutics has reported promising long-term data from its open-label study on Friedreich's ataxia, highlighting consistent improvements across four key clinical outcomes and increased skin frataxin levels. The company is adjusting its dosing regimen to mitigate anaphylactic risks, aiming for a Biologics License Application by Q2 2026. Larimar's financial metrics indicate a challenging environment with a focus on strategic development and regulatory progress.